Potential Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Diabetes and High Risk for Dementia

Germán Plascencia‐Villa; Rong Xu; George Perry

doi:10.7326/annals-25-02362

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2017

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

M. Angelyn Bethel, Rishi Patel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Robert J. Mentz, Neha J. Pagidipati, Juliana C.N. Chan, Stephanie M. Gustavson, Nayyar Iqbal, Aldo Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez, Rury R. Holman

Article2025

Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study

Feyzullah Aksan, Alan Abboud, Lokman Hekim Tanrıverdi, Olga C. Aroniadis, Farah Monzur

Article2024

SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation

Yi‐Hsin Chan, Tze‐Fan Chao, Shao-Wei Chen, Hsin‐Fu Lee, Pei‐Ru Li, Yung‐Hsin Yeh, Chi‐Tai Kuo, Lai‐Chu See, Professor Gregory Lip

Letter2025

GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes?

Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi

Article2022

Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective

Poonam Yadav, Amit Khurana, Jasvinder Singh Bhatti, Ralf Weiskirchen, Umashanker Navik